Effects of the menopause hormone therapy on the immune system;Efeitos da terapia hormonal na menopausa sobre o sistema imune

Revista Brasileira de Ginecologia e Obstetricia

Volumn 29, Issue 11, 2007, Pages 593-601

  De Mederos, Sebastião Freitas ^a,b,c   Maitelli, Alexandre ^d   Nince, Ana Pauia Barros ^e  

^a Universidade Federal de Mato Grosso UFMT ^*  (United States)

^b UNIVERSIDADE FEDERAL DE MATO GROSSO   (Brazil)

^c Instituto Tropical de Medicina Reprodutiva e Menopausa   (Brazil)

^d HOSPITAL UNIVERSITÁRIO JÚLIO MÜLLER   (Brazil)

^e FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

Author keywords

Cytokines; Hormone replacement therapy; Immune system; Menopause; Steroids

Indexed keywords

EID: 41149176537     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Medeiros SF, Medeiros MMWY, Oliveira VN. Climacteric complaints among very low-income women from a tropical region of Brazil. Säo Paulo Med J. 2006; 124(4):214-8.
2. Miller RA. The aging immune system: primer and prospectus. Science. 1996;273(5271):70-4.
3. Straub RH, Cutolo M, Zietz B, Scholmerich J. The process of aging changes the interplay of the immune, endocrine and nervous systems. Mech Ageing Dev. 2001;122(14): 1591-611.
4. Kishimoto S, Tomino S, Mitsuya H, Nishimura H. Age-related decrease in frequencies of B-cell precursors and specific helper T cells involved in the IgG anti-tetanus toxoid antibody production in humans. Clin Immunol Immunopathol. 1982;25(1): 1-10.
5. Grossman CJ, Rossele GA, Mendenhall CL. Sex steroid regulation of autoimmunity. J Steroid Biochem Mol Biol. 1994;40(4-6):649-59.
6. Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol. 2003;38(1): 13-22.
7. Basedovsky HO, Del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev. 1996;17(1):64-102.
8. Russell DH. New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol Sci. 1989;10(1):40-4.
9. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol. 2002;20:125-63.
10. Ho HN, Wu MY, Chen HF, Chao KH, Yang YS, Huang SC, et al. In vivo CD3+CD25+ lymphocyte subpopulation is down-regulated without increased serum-soluble interleukin-2 receptor (slL-2R) by gonadotropin releasing hormone agonist (GnRH-a). Am J Reprod Immunol. 1995;33(1): 134-9.
11. Silveira LF, Stewart PM, Thomas M, Clark DA, Bouloux PM, MacColl GS. Novel homozygous splice acceptor site GnRH receptor (GnRHR) mutation: human GnRHR 'knockout'. J Clin Endocrinol Metab. 2002;87(6):2973-7.
12. Rivest S, Rivier C. The role of corticotropin-releasing factor and interleukin-1 in the regulation of neurons controlling reproductive function. Endocr Rev. 1995; 16(2): 177-99.
13. Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA, et al. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med. 1995; 1 (12):1279-83.
14. Pelfrey CM. Sexual dimorphism in autoimmunity: a focus on Th 1/ Th2 cytokines and multiple sclerosis. Clin Appl Immunol Rev. 2001;1(6):331-45.
15. Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol. 1999; 103(2 Pt 1):282-8.
16. Hong SC, Yoo SW, Cho GJ, Kim T, Hur JY, Park YK, et al. Correlation between estrogens and serum adipocytokines in premenopausal and postmenopausal women. Menopause. 2007;14(5):835-40.
17. DeLoia J, Stewart-Akers AM, Brekosky J, Kubik CJ. Effects of exogenous estrogen on uterine leukocyte recruitment. Fertil Steril. 2002;77(3):548-54.
18. Jain SK, Kannan K, Prouty L, Jain SK. Progesterone, but not 17β-estradiol, increases TNF-α secretion in U937 monocytes. Cytokine. 2004;26(3): 102-5.
19. Prabhala RH, Fahey JV, Humphrey SL, Edkins RD, Stern JE, Wira CR. Regulation by human uterine cells of PBMC proliferation: influence of the phase of the menstrual cycle and menopause. J Reprod Immunol. 1998;40(1):25-45.
20. Grossman CJ. Regulation of the immune system by sex steroids. Endocr Rev. 1984;5(3):435-55.
21. Luchetti CG, Solano ME, Sander V, Arcos ML, Gonzalez C, Di Girolamo G, et al. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J Reprod Immunol. 2004;64(1-2):59-74.
22. Arlt W, Hewison M. Hormonesand immune function: implications of aging. Aging Cell. 2004;3(4):209-16.
23. Faas M, Bouman A, Moes H, Heineman MJ, de Leij L, Schuiling G. The immune response during the luteal phase of the ovarian cycle: a Th2-type response? Fertil Steril. 2000;74(5): 1008-13.
24. Shakhar K, Shakhar G, Rosenne E, Ben-Eliyahu S. Timing within the menstrual cycle, sex, and the use of oral contraceptives determine adrenergic suppression of NK cell activity. Br J Cancer. 2000;83(12): 1630-6.
25. White HD, Crassi KM, Givan AL, Stern JE, Gonzalez JL, Memoli VA, et al. CD3+CD8+CTL activity within the human female reproductive tract: influence of stage of menstrual cycle and menopause. J Immunol. 1997;158(6):3017-27.
26. Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol. 1996;31(1):81-95.
27. Olsen NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev. 1996;17(4):369-84.
28. Medeiros SF, Oliveira VN, Yamamoto MMW. Epidemiologia clínica do climatério. Reprod Clim. 2003; 18(1):79-86.
29. Keller ET, Zhang J, Yao Z, Qi Y. The impact of chronic estrogen deprivation on immunologic parameters in the ovariectomized rhesus monkey (Macaca mulatto) model of menopause. J Reprod Immunol. 2001;50(1):41-55.
30. Verthelyi D, Klinman DM. Sex hormone levels correlate with the activity of cytokine-secreting cells in vivo. Immunology. 2000;100(3):384-90.
31. Giglio T, Imro MA, Filaci G, Scudeletti M, Puppo F, De Ceceo L, et al. Immune cell circulating subsets are affected by gonadal function. Life Sci. 1994;54(18): 1305-12.
32. Yang JH, Chen CD, Wu MY, Chao KH, Yang YS, Ho HN. Hormone replacement therapy reverses the decrease in natural killer cytotoxicity but does not reverse the decreases in the T-cell subpopulation or interferon-gamma production in postmenopausal women. Fertil Steril. 2000;74(2):261-7.
33. Kumru S, Godekmerdan A, Yilmaz B. Immune effects of surgical menopause and estrogen replacement therapy in peri-menopausal women. J Reprod Immunol. 2004;63(1):31-8.
34. Kamada M, Irahara M, Maegawa M, Ohmoto Y, Takeji T, Yasui T, et al. Postmenopausal changes in serum cytokine levels and hormone replacement therapy. Am J Obstet Gynecol. 2001;184(3):309-14.
35. Yasui T, Maegawa M, Tomita J, Miyatani Y, Yamada M, Uemura H, et al. Changes in serum cytokine concentrations during the menopausal transition. Maturitas. 2007;56(4):396403.
36. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23(1):90-119.
37. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab. 2000;85(3): 1340-4.
38. Brooks-Asplund EM, Tupper CE, Daun JM, Kenney WL, Cannon JG. Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. Cytokine. 2002; 19(4): 193-200.
39. Morishita M, Miyagi M, Iwamoto Y. Effects of sex hormones on production of interleukin-1 by human peripheral monocytes. J Periodontal. 1999;70(7):757-60.
40. Medeiros SF, Nince APB. Efeito da terapia de reposição hormonal sobre o sistema imune no climatério. Anais do XII Encontro de Iniciação Científica da UFMT; 15-16 jul 2004; Cuiabá; 2004. p. 269.
41. Manyonda IT, Pereira RS, Makinde V, Brincat M, Varma RT. Effect of 17β-oestradiol on lymphocyte subpopulations, delayed cutaneous hypersensitivity responses and mixed lymphocyte reactions in post-menopausal women. Maturitas. 1992;14(3):201-10.
42. Hough HJ, Failla ML, Ludwig DA. Active lifestyle offsets HRT-induced suppression of T cell reactivity to mitogens. Maturitas. 1999;33(3):211-8.
43. Albrecht AE, Hartmann BW, Scholten C, Huber JC, Kalinowska W, Zielinski CC. Effect of estrogen replacement therapy on natural killer cell activity in postmenopausal women. Maturitas. 1996;25(3):217-22.
44. Fahlman MM, Boardley D, Flynn MG, Bouillon LE, Lambert CP, Braun WA. Effects of hormone replacement therapy on selected indices of immune function in postmenopausal women. Gynecol Obst Invest. 2000;50(3):1 89-93.
45. Stopinska-Gluszak U, Waligóra J, Grzela T, Gluszak M, Jozwiak J, Radomski D, et al. Effect of estrogen/progesterone hormone replacement therapy on natural killer cell cytotoxicity and immunoregulatory cytokine release by peripheral blood mononuclear cells of postmenopausal women. J Reprod Immunol. 2006;69(1):65-75.
46. Porter VR, Greendale GA, Schocken M, Zhu X, Effros RB. Immune effects of hormone replacement therapy in post-menopausal women. Exp Gerontol. 2001;36(2):311-26.
47. Deguchi K, Kamada M, Irahara M, Maegawa M, Yamamoto S, Ohmoto Y, et al. Postmenopausal changes in production of type 1 and type 2 cytokines and the effects of hormone replacement therapy. Menopause. 2001;8(4):266-73.
48. Reuben DB, Palla SL, Hu P, Reboussin BA, Crandall C, Herrington DM, et al. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Am J Med. 2006;119(2):167.e1-8.
49. Rogers A, Eastell R. Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood. J Bone Mineral Res. 1998; 13(10): 1577-86.
50. Berg G, Ekerfelt C, Hammar M, Lindgren R, Matthiesen L, Ernerudh J. Cytokine changes in postmenopausal women treated with estrogens: a placebo-controlled study. Am J Reprod Immunol. 2002;48(2):63-9.
51. Yilmazer M, Fenkci V, Fenkci S, Aktepe O, Sonmezer M, Kurtay G. Association of serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels with hormone replacement therapy in healthy post-menopausal women. Hum Reprod. 2003; 18(7): 1531-5.
52. Christodoulakos GE, Lambrinoudaki IV, Economou EV, Papadias C, Vitoratos N, Panoulis CP, et al. Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-I are differentially suppressed by hormone therapy and raloxifene. Atherosclerosis. 2007;193(1): 142-50.
53. Stanczyk FZ. Parenteral versus oral treatment of postmenopausal women with estrogen. Menopause. 2007 Sep 25 [Epub ahead of print]
54. Hu P, Greendale GA, Palla SL, Reboussin BA, Herrington DM, BarrettConnor E, et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis. 2006;1 85(2):347-52.
55. de Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-years, placebo-controlled study. Arterioscler Thromb Vase Biol. 1999;19(12):2993-3000.
56. Abbas A, Fadel PJ, Wang Z, Arbique D, Jialal I, Vongpatanasin W. Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoproteins: SAA in postmenopausal women. Arterioscler Tromb Vase Biol. 2004;24(10):e164-7.
57. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative Observational Study. JAMA. 2002;288(8):980-7.
58. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation. 2002;105(12):1436-9.
59. Menon DV, Vongpatanasin W. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors.Treat Endocrinol. 2006;5(1):37-51.
60. Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas. 2006;53(3):252-9.
61. Kwok S, Charlton-Menys V, Pemberton P, McElduff P, Durrington PN. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. Maturitas. 2006;53(4):439-46.